Skip to main content
Log in

FDG-PET as a Prognostic Factor in High-grade Astrocytoma

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Background: The prognostic value of the metabolic status of cerebral gliomas determined by positron emission tomography with [18F]-fluoro-deoxy-D-glucose (FDG-PET) has been established in populations with a mixture of grades 2, 3 and 4 gliomas, but remains uncertain when only malignant gliomas are considered (grade 3 and 4).

Methods: FDG-PET performed in 30 patients with anaplastic astrocytoma (grade III) and 61 patients with glioblastoma (grade 4) were classified according to a metabolic grading. The uptake of FDG was lower in the tumor compared to white matter (WM) in grade 1 (4 glioblastoma, 4 anaplastic astrocytoma), it was intermediate between WM and cortex in grade 2 (20 glioblastoma, 22 anaplastic astrocytoma), and it was superior to cortex in grade 3 (38 glioblastoma, 4 anaplastic astrocytoma).

Results: Kaplan–Meier survival curves were similar in patient with grades 1 and 2, but were significantly worse (p = 0.007) in grade 3. In multivariate analysis considering age, pathological grade (anaplastic astrocytoma versus glioblastoma), and metabolic grades, the metabolic grade did not appear to be an independent prognostic factor. When anaplastic astrocytomas and glioblastomas were considered separately, metabolic grade is of predictive value only in the group of glioblastomas.

Conclusion: In malignant gliomas, metabolic grading determined by FDG-PET was not superior to the pathological grading for survival prediction. Still, it remains of predictive value when applied to malignant gliomas histologically classified as glioblastoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Keles GE, Anderson B, Berger M: The effect of extent of resection on the time to progression in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52: 371-379, 1999

    Google Scholar 

  2. De Witte O, Levivier M, Violon P, Salmon I, Damhaut P, Wikler D, Hildebrand J, Brotchi J, Goldman S: Prognostic value of positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery 39: 470-476, 1996

    Google Scholar 

  3. Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH: Glucose utilization of cerebral gliomas measured by [18F]fluorodeoxyglucose and positron emission tomography. Neurology 32: 1323-1329, 1982

    Google Scholar 

  4. Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, Larson SM: Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 62: 816-822, 1985

    Google Scholar 

  5. De Witte O, Hildebrand J, Luxen A, Goldman S: Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer 74: 2836-2842, 1994

    Google Scholar 

  6. O'Neil A, Macapinlac H, DeAngelis L: Positron emission tomography hypermetabolism with cerebral radionecrosis (abstract). Proceedings of the Eleventh International Conference on Brain Tumor Research and Therapy, 1995, p 23

  7. Kleihues P, Burger PC, Scheithauer BW: The new WHO classification of brain tumours. Brain Pathol 3: 255-268, 1993

    Google Scholar 

  8. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N: Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studies by microautoradiography. J Nucl Med 33: 1972-1980, 1992

    Google Scholar 

  9. Levivier M, Goldman S, Bidaut L, Luxen A, Stanus E, Przedborski S, Baleriaux D, Hildebrand J, Brotchi J: Positron emission tomography-guided stereotaxic brain biopsy. Neurosurgery 31: 792-797, 1992

    Google Scholar 

  10. Hamacher K, Coenen HH, Stöcklin G: Efficient stereospecific synthesis of no-carrier-added 2-[18F]fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27: 235-238, 1986

    Google Scholar 

  11. Di Chiro G, Brooks RA, Patronas NJ, Bairamian D, Kornblith PL, Smith BH, Mansi L, Barker J: Issues in the in vivo measurement of glucose metabolism of human central nervous system tumors. Ann Neurol, 15(suppl): S138-S146, 1984

    Google Scholar 

  12. Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W, Reivich M: Positron emission tomography in patients with glioma. Cancer 62: 1074-1078, 1988

    Google Scholar 

  13. Di Chiro G: Positron emission tomography using [18F]Fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol 22: 360-371, 1986

    Google Scholar 

  14. De Kim C, Alavi JB, Alavi A, Reivich M: New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neuro-Oncol 10: 85-91, 1996

    Google Scholar 

  15. Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, Stanus E, Brotchi J, Hildebrand J: Regional glucose metabolism and histopathology of gliomas. Cancer 78, 1098-1106, 1996

    Google Scholar 

  16. Kubota R, Kubota K, Yamada S, Tada M, Tamahashi N: Active and passive mechanism of [fluorine-18]fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: a microautoradiography study. J Nucl Med 35: 1067-1075, 1994

    Google Scholar 

  17. De Witte O, Levivier M, Violon P, Brotchi J, Goldman S: Quantitative imaging study of extent of surgical resection and prognosis of malignant astocytomas. Neurosurgery, 43: 398-399, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Witte, O., Lefranc, F., Levivier, M. et al. FDG-PET as a Prognostic Factor in High-grade Astrocytoma. J Neurooncol 49, 157–163 (2000). https://doi.org/10.1023/A:1026518002800

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026518002800

Keywords